{\rtf1\ansi\ansicpg1252\cocoartf2821
\cocoatextscaling0\cocoaplatform0{\fonttbl\f0\fswiss\fcharset0 Helvetica;}
{\colortbl;\red255\green255\blue255;}
{\*\expandedcolortbl;;}
\margl1440\margr1440\vieww11520\viewh8400\viewkind0
\pard\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\pardirnatural\partightenfactor0

\f0\fs24 \cf0 \{\
  "Recurrent Disease": \{\
    "Indications": [\
      "Rising or newly elevated Tg or Tg ab and negative imaging",\
      "Non-resectable tumors",\
      "Non-radioiodine responsive"\
    ],\
    "Initial Management": \{\
      "Action": "Suppress TSH with levothyroxine",\
      "Follow-up": "Continue surveillance with Tg, ultrasound, and other imaging as clinically indicated (ONC-6)"\
    \},\
    "Locoregional recurrence": \{\
      "Step": "Consider iodine total body scan",\
      "Treatment options": [\
        \{\
          "If resectable": [\
            "Surgery (preferred)",\
            "Consider RAI therapy if preoperative or postoperative radioiodine imaging is positive"\
          ]\
        \},\
        \{\
          "If non-progressive disease stable and distant from critical structures": "Disease monitoring"\
        \},\
        \{\
          "If unresectable, non\'96radioiodine-avid, and progressive disease": [\
            "Radiation therapy (RT)",\
            "Systemic therapies (Treatment [ONC-9])"\
          ]\
        \},\
        \{\
          "If limited burden nodal disease": "Consider local therapies when available (e.g., ethanol ablation, RFA)"\
        \}\
      ]\
    \},\
    "Metastatic disease": \{\
      "Treatment options": [\
        "RAI therapy for iodine-avid disease",\
        "Local therapies when available",\
        "Treatment (ONC-9)"\
      ]\
    \}\
  \}\
\}\
}